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Assessment of coronary reperfusion in patients
with myocardial infarction using fatty acid binding
protein concentrations in plasma
M J M de Groot, A M MMuijtjens, M L Simoons, W T Hermens, J F C Glatz
Abstract
Objective—To examine whether successful coronary reperfusion after thrombolytic treatment in
patients with confirmed acute myocardial infarction can be diagnosed from the plasma marker fatty
acid binding protein (FABP), for either acute clinical decision making or retrospective purposes.
Design—Retrospective substudy of the GUSTO trial.
Setting—10 hospitals in four European countries.
Patients—115 patients were treated with thrombolytic agents within six hours after the onset of
acute myocardial infarction. Patency of the infarct related artery was determined by angiography
within 120 minutes of the start of thrombolysis.
Main outcome measures—First hour rate of increase in plasma FABP concentration after
thrombolytic treatment, compared with increase in plasma myoglobin concentration and creatine
kinase isoenzyme MB (CK-MB) activity. Infarct size was estimated from the cumulative release
of the enzyme á hydroxybutyrate dehydrogenase in plasma during 72 hours, or from the sum of
ST segment elevations on admission. Logistic regression analyses were performed to construct
predictive models for patency.
Results—Complete reperfusion (TIMI 3) occurred in 50 patients, partial reperfusion (TIMI 2)
in 36, and no reperfusion (TIMI 0+1) in 29. Receiver operating characteristic (ROC) curve
analyses showed that the best performance of FABP was obtained when TIMI scores 2 and 3
were grouped and compared with TIMI score 0+1. The performance of FABP as a reperfusion
marker was improved by combining it with á hydroxybutyrate dehydrogenase infarct size, but not
with an early surrogate of infarct size (ST segment elevation on admission). In combination with
infarct size FABP performed as well as myoglobin (areas under the ROC curve 0.868 and 0.857,
respectively) and better than CK-MB (area = 0.796). At optimum cut oV levels, positive predic-
tive values were 97% for FABP, 95% for myoglobin, and 89% for CK-MB (without infarct size,
87%, 88%, and 87%, respectively), and negative predictive values were 55%, 52%, and 50%,
respectively (without infarct size, 44%, 42%, and 34%).
Conclusions—FABP and myoglobin perform equally well as reperfusion markers, and success-
ful reperfusion can be assessed, with positive predictive values of 87% and 88%, or even 97% and
95% when infarct size is also taken into account. However, identification of non-reperfused
patients remains a problem, as negative predictive values will generally remain below 70%.
(Heart 2001;85:278–285)
Keywords: myocardial reperfusion; cardiac marker proteins
Thrombolytic treatment has become impor-
tant in patients with acute myocardial infarc-
tion in order to reopen the infarct related artery
and improve the survival of heart muscle.
However, when this treatment has failed the
patient may need other interventions such as
angioplasty. In order to reach a decision on
this, it is important to make a rapid, accurate,
and non-invasive evaluation of the reperfusion
status of the infarct related coronary artery
after initial thrombolytic treatment. Relief of
chest pain, normalisation of ST segment eleva-
tion on the ECG, and the occurrence of
specific arrhythmias have been used as markers
of reperfusion, but their sensitivity and specifi-
city are limited.1 2 In addition, early washout
and peaking of various cardiac proteins such as
creatine kinase, creatine kinase MB isoenzyme
(CK-MB), and myoglobin have been used to
identify coronary reperfusion.3–6 Of these bio-
chemical markers, myoglobin has been found
most valuable because of its rapid release after
opening of the vessel.3 6 7 More recently, a new
plasma marker—fatty acid binding protein
(FABP)—has become available, which resem-
bles myoglobin in size (15 kDa), in its abun-
dant presence in the cytoplasm of cardiomyo-
cytes, and in its similarly rapid release into
plasma after reperfusion.8 9 FABP has been
found superior to myoglobin for the early
detection of acute myocardial infarction.10 11
It was our aim in the present study to evalu-
ate whether FABP can be used as a marker,
either in acute clinical situations or retrospec-
tively, to distinguish successful reperfusion
from persistent occlusion after thrombolytic
treatment in patients with confirmed acute
myocardial infarction. We determined the
increase in plasma concentrations of FABP in
the first hour after thrombolytic treatment, and
we also examined the increases occurring from
1–3 hours after thrombolysis as well as certain
clinical variables (treatment delay, delay in per-
forming angiography, infarct location). A com-
parison was made with the established markers
myoglobin and CK-MB. The increase in
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cardiac proteins in the plasma after infarction is
dependent on infarct size. We therefore as-
sessed infarct size by an established method—
the cumulative release of á hydroxybutyrate
dehydrogenase during the first 72 hours after
infarction.12 However, only a retrospective
assessment of reperfusion status can be ob-
tained in this way, though acute assessment is
clinically more relevant. We therefore at-
tempted to use an early surrogate for infarct
size—initial ST segment elevation on the ECG.
Methods
PATIENTS
Data were obtained from 124 patients with
confirmed acute myocardial infarction, en-
rolled in the GUSTO (global utilisation of
streptokinase and tissue plasminogen activator
for occluded coronary arteries) enzyme sub-
study.13 Inclusion criteria for enrolment into
the GUSTO study have been described in
detail elsewhere.14 In summary, patients were
eligible when they were admitted to hospital
within six hours after the onset of symptoms,
had chest pain lasting for at least 20 minutes,
and showed ECG evidence of acute myocardial
infarction (> 0.1 mV of ST segment elevation
in two or more limb leads, or > 0.2 mV in two
or more contiguous precordial leads). Patients
suspected of acute myocardial infarction re-
ceived one of four intravenous thrombolytic
regimens: streptokinase with subcutaneous
heparin; streptokinase with intravenous
heparin; accelerated tissue plasminogen activa-
tor (t-PA) with intravenous heparin; or the
combination of t-PA and streptokinase, along
with intravenous heparin.
Following thrombolytic treatment, coronary
angiography was performed within 120 min-
utes (mean (SEM) 1.6 (0.2) hours, range 0.9–
2.0 hours) to determine the reperfusion status
of the infarct related artery. Flow in the infarct
related artery was graded according to the
thrombolysis in myocardial infarction (TIMI)
trial classification.15 Coronary arteries with
TIMI grade 3 flow were regarded as success-
fully reperfused. Coronary arteries with TIMI
grade 2 flow were regarded as partially open.
TIMI grade 0 or 1 defined persistent occlu-
sion.
BLOOD SAMPLING
Blood samples were collected immediately
before and at 1, 3, 6, 12, 18, 24, 36, 48, 72, and
96 hours after the start of thrombolytic
treatment, resulting in 11 samples/patient.
Exact sampling time was recorded on the
GUSTO enzyme case report form.13 Samples
were collected in glass tubes containing dry
heparin to prevent clotting. After routine
centrifugation, plasma was kept at −20°C in
the local hospital and within eight weeks was
transported in polystyrene boxes with dry ice to
the central laboratory at Maastricht, Nether-
lands, and stored at −80°C until assays were
performed.
ANALYTICAL TECHNIQUES
Heart type FABP was measured in duplicate in
plasma samples by a non-competitive enzyme
linked immunosorbent assay (ELISA) as de-
scribed elsewhere,16 using an incubation time
of 60 minutes. Samples were diluted with
phosphate buVered saline (pH 7.4) containing
0.1% bovine serum albumin and 0.05%
Tween-20. The detection limit of the assay was
0.2 µg/l. Quality control was performed with
human plasma, spiked with recombinant
human FABP. Intra-assay and interassay im-
precision values were 4.2% and 9.0%, respec-
tively. Myoglobin was determined in duplicate
by a turbidimetric immunoassay (Unimate 3
Myo, art 0751839, Roche, Mijdrecht, Nether-
lands) on a Cobas Fara analyser (Roche Diag-
nostic Systems, Basel, Switzerland). Plasma
samples were diluted with saline (0.9% NaCl).
For quality control a commercial standard was
used (Roche, art 075186). Intra-assay and
interassay imprecision values were 3.5% and
4.0%, respectively. It has been reported in
detail previously that FABP and myoglobin
concentrations in plasma stored at −80°C, as in
the present study, remain stable for several
years.17 Plasma concentrations of FABP and
myoglobin are expressed in µg/l.
Activities of CK-MB and á hydroxybutyrate
dehydrogenase were measured spectrophoto-
metrically in duplicate at 25°C, using a
centrifugal analyser (Cobas Bio System,
Roche) and commercially available test kits.
The CK-MB test is based on immunoinhibi-
tion of the predominant M unit in creatine
kinase (Boehringer Mannheim, Mannheim,
Germany). The á hydroxybutyrate dehydroge-
nase test is based on the preferential catalytic
activity of the myocardial isoforms LDH1 and
LDH2 of lactate dehydrogenase in the conver-
sion of á ketobutyrate, instead of pyruvate
(Diagnostica Merck, Darmstadt, Germany).
Quality control was performed using a com-
mercially available control serum (Precipath,
Boehringer Mannheim). Intra-assay and inte-
rassay imprecision values were 3.2% and 6.6%
for CK-MB and 2.4% and 4.4% for á
hydroxybutyrate dehydrogenase. Activities are
expressed in micromoles of substrate converted
per minute and litre of plasma (U/l).
CALCULATION OF THE INCREASE RATE OF PLASMA
FABP, MYOGLOBIN, AND CK-MB
The first hour increases in plasma FABP,
myoglobin, and CK-MB release were calcu-
lated by the diVerence in plasma concentra-
tions or activity between the first two
samples—that is, the samples just before
(−0.11 (0.02) hours) and about one hour (1.14
(0.03)) after thrombolytic treatment, divided
by the exact time between these two samples.
The increase in plasma FABP, myoglobin, and
CK-MB release was also determined from 1–3
hours (2.97 (0.02)) after thrombolytic treat-
ment. The increase rates are expressed in µg/l/
hour for FABP and myoglobin, and in U/l/hour
for CK-MB.
DETERMINATION OF ENZYMATIC INFARCT SIZE
Infarct size was calculated from the cumulative
release of á hydroxybutyrate dehydrogenase
activity during 72 hours. Cumulative release of
á hydroxybutyrate dehydrogenase per litre of
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plasma, from the onset of acute myocardial inf-
arction (t = 0) up to time t, is indicated as Q(t)
and was calculated from the following expres-
sion12:
The three terms are the quantity of released
protein still present in plasma at time t, the
extravasated quantity of protein at time t, and
the quantity of protein eliminated from plasma
up to time t, all three being expressed per litre
of plasma.
C(t) is the plasma protein concentration or
enzyme activity at time t, corrected by subtrac-
tion of normal steady state values, Cs. The lat-
ter were obtained from the lowest plasma values
if they did not exceed the maximum value of
120 U/l for á hydroxybutyrate dehydrogenase.
Otherwise, fixed mean values of 82 U/l were
used. The variables TER and ERR represent
the fractional rate constants for transcapillary
escape and extravascular return of protein.
Parameter values for á hydroxybutyrate dehy-
drogenase in man are TER = 0.014/h and
ERR = 0.018/h.12 FCR is the fractional cata-
bolic rate constant for the elimination of
protein from plasma (0.015/h). Infarct size is
expressed in gram equivalents of myocardium/
litre of plasma (g eq/l). To this end, cumulative
release of á hydroxybutyrate dehydrogenase/
litre of plasma was divided by the mean
myocardial content of á hydroxybutyrate de-
hydrogenase/g wet weight of tissue (123 U/g).
ST SEGMENT ELEVATION
The sum of ST segment elevations was
obtained from admission ECG recordings. ST
segment elevation and depression were
measured at the J point of the ECG. The
degree of elevation or depression was measured
in millivolts. Total ST segment elevations were
calculated as described elsewhere.18
DATA ANALYSIS
Data analysis was performed with standard
software (SPSS). Mean values (SEM) were
calculated. DiVerences between the rates of
increase in the TIMI groups were tested by the
non-parametric Mann–Whitney rank test.
Predictive models for patency were con-
structed using logistic multiple regression.This
method can be used when a binary classifi-
cation, such as reperfusion versus non-
reperfusion, is explained or predicted by a set
of continuous variables19 (for example, first
hour increase rate of a plasma marker concen-
tration, infarct size, and so on). In the
corresponding model the log odds of the prob-
ability of reperfusion (q) was expressed as a
linear function of the explaining variables:
log(q/(1−q)) = b0 + b1 × (first hour increase of
FABP) + b2 × (infarct size).
Variables that contributed significantly to
correct prediction of the classification were
identified in a stepwise logistic regression pro-
cedure. Estimates of the variables b0, b1, . . .
were obtained and for each case the estimated
probability of reperfusion, q, was calculated. In
our approach, q was used as an indicator of
reperfusion analogous to the outcome in a
diagnostic test. High values of q indicated
reperfusion, low values indicated that reper-
fusion was not obtained. In order to distinguish
high and low values, a cut oV for q is required.
In a receiver operating characteristic (ROC)
curve, analysis of the relation between q and
reperfusion, indicated by the TIMI score (true
classification), was investigated for varying lev-
els of cut oV. The predictive value of a combi-
nation of predictors could thus be evaluated in
a standard ROC analysis.
The sensitivity, specificity, positive predictive
value (PPV), and negative predictive value
(NPV) were determined as follows:
Sensitivity—percentage of correctly identified
patients with patent (TIMI 2 or 3) infarct
related artery;
Specificity—percentage of correctly identified
patients with occluded (TIMI 0 or 1) infarct
related artery;
PPV—percentage of correctly identified pa-
tients with reperfusion;
NPV—percentage of correctly identified pa-
tients with occlusion.
Plots were made of the sensitivity (true posi-
tive rate) against 1 − specificity (false positive
rate) (ROC curve), and statistical comparison
of the areas under the curve was performed
according to a previously described method.20
Relations between variables were calculated by
Pearson’s correlation coeYcients. Probability
values of p < 0.05 were considered significant.
Results
PATIENTS
Patients who had cardioversion (n = 9) were
excluded from the present study because of
possible skeletal muscle damage. Baseline
characteristics of the remaining 115
patients—93 men and 22 women—are shown
in table 1. Except for the percentage of women,
there were no significant diVerences in baseline
characteristics, so for further analysis data from
the four treatment groups were taken together.
Fifty patients (43%) obtained a TIMI 3 score
after angiography, 36 patients (31%) obtained
a TIMI 2 score, while the other 29 patients
(25%) had a score of TIMI 0 or 1. For the 115
patients studied, all variables that might be
associated with reperfusion were complete.
PREDICTION OF REPERFUSION CONSIDERING TIMI
3 SCORE SEPARATELY OR COMBINED WITH TIMI
SCORE 2
The concentrations of FABP, myoglobin, and
CK-MB in plasma samples obtained immedi-
ately before thrombolytic treatment did not
diVer significantly among the TIMI score
groups (data not shown). One hour after
thrombolytic treatment, plasma FABP, my-
oglobin, and CK-MB concentrations had
increased significantly more in the TIMI 2 and
3 patients (p < 0.005 for FABP and my-
oglobin, p < 0.05 for CK-MB) than in the
TIMI 0 or TIMI 1 patients, but for each
280 de Groot,Muijtjens, Simoons, et al
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marker the increases were not significantly dif-
ferent between the TIMI 2 and TIMI 3
patients (fig 1 and data not shown).
Figure 2A shows the ROC curves of the first
hour increase in FABP release when patency
was defined as TIMI 3 alone or as TIMI 2+3,
and occlusion was defined as either TIMI 0+1
or TIMI 0+1+2. The area under the ROC
curve was highest when TIMI 2+3 values were
compared with TIMI 0+1 (area = 0.760),
slightly smaller when TIMI 3 was compared
with TIMI 0+1 (area = 0.706, p < 0.05), and
smallest when TIMI 3 was compared with
TIMI 0+1+2 (area = 0.530, p < 0.001). For
myoglobin similar results were obtained (data
not shown). Further analysis was therefore
performed on the TIMI 2+3 patients versus
the TIMI 0+1 patients. The probability of
reperfusion (q) on the basis of the first hour
increase rate of FABP could be estimated by
log (q/1−q) = 0.1367 + 0.0097 × (first hour
increase rate of FABP).
PREDICTION OF REPERFUSION BY FABP, PATIENT
CHARACTERISTICS, CLINICAL VARIABLES, AND
INFARCT SIZE
We attempted to improve discrimination be-
tween reperfused (TIMI 2+3) and non-
reperfused patients (TIMI 0+1) by combining
the first hour increase in FABP release with the
1–3 hour increase in FABP release, some char-
acteristics of the patients (age, sex), clinical
variables (treatment delay, catheterisation
delay, infarct location), and infarct size (as
measured either by the cumulative release of á
hydroxybutyrate dehydrogenase into plasma in
the first 72 hours (QHBDH72) or by ST
segment elevation). Forward stepwise logistic
regression analysis indicated that prediction of
reperfusion was not improved by adding the
1–3 hour increase in FABP release, the patient
characteristics, or the clinical variables to the
model (p > 0.05), nor did the addition of
infarct size, as measured by ST segment eleva-
tion, improve discrimination between reper-
fused and non-reperfused patients (fig 2B, area
under the ROC curve 0.772). In contrast, the
addition of infarct size as measured by
QHBDH72 did improve discrimination be-
tween reperfused and non-reperfused patients
(fig 2B, area under the ROC curve 0.868,
p < 0.001).
The probability of reperfusion (q) on basis of
the first hour increase in FABP release and
enzymatic infarct size could be estimated by:
Table 1 Baseline characteristics of the diVerent treatment groups
All patients
SK with sc
heparin
SK with iv
heparin
tPA with iv
heparin
SK + tPA
with iv
heparin
Baseline variables
Number of patients 115 32 18 39 26
Age (years) 59 (1) 61 (2) 62 (2) 58 (2) 57 (2)
Female sex (%) 19 19 39 21 4
Infarct location (%)
Anterior 45 41 39 51 46
Inferior 49 50 61 46 46
Other 5 9 0 3 8
Previous AMI (%) 16 21 13 16 14
Previous CABG (%) 3 3 4 2 4
Time to treatment (h) 3.1 (0.1) 2.9 (0.2) 3.2 (0.3) 3.2 (0.2) 3.1 (0.3)
Time to angiography (h) 1.6 (0.02) 1.6 (0.02) 1.6 (0.06) 1.6 (0.03) 1.6 (0.03)
Clinical events
Stroke, all types (%) 2 3 0 0 4
Shock (%) 2 0 4 2 4
Angioplasty (%) 9 18 17 4 0
30 day mortality (%) 3 3 4 2 3
TIMI score (number of patients)
0 23 14 4 4 1
1 6 2 4 0 0
2 36 11 4 12 9
3 50 5 6 23 16
Infarct size calculated from
HBDH (g eq/l)
4.8 (0.3) 5.3 (0.5) 5.3 (1.0) 4.3 (0.5) 4.7 ( 0.8)
Data are expressed as mean (SEM) or per cent unless specified.
AMI, acute myocardial infarction; CABG, coronary artery bypass graft; iv, intravenous; sc,
subcutaneous; SK, streptokinase; TIMI, thrombolysis in myocardial infarction grade; t-PA, accel-
erated tissue plasminogen activator.
Figure 1 The first hour increase in plasma fatty acid
binding protein (FABP) release in patients with TIMI
grade 0 (n = 23), TIMI 1 (n = 6), TIMI 2 (n = 36), and
TIMI 3 (n = 50). In the TIMI 0+1, TIMI 2, and TIMI 3
patients the mean (SEM) increases were 50 (11), 283
(53), and 232 (45) µg/l/h.
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Figure 2 (A) Receiver operating characteristic (ROC)
curves (sensitivity v 1 − specificity) for the first hour
increase of fatty acid binding protein (FABP) release,
comparing TIMI grade 3 v TIMI 0+1+2 (empty
triangles), TIMI 3 v TIMI 0+1 (filled circles), and TIMI
2+3 v TIMI 0+1 (empty squares). (B) ROC curves of the
first hour increase rate of FABP (filled circles), the first
hour increase rate of FABP and QHBDH72 (empty
squares), and the first hour increase rate of FABP plus the
sum of ST segment elevations (empty triangles), for TIMI
2+3 v TIMI 0+1.QHBDH72, cumulative release of á
hydroxybutyrate dehydrogenase into plasma in the first 72
hours.
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log (q/1−q) = 1.6542 + 0.0132 × (first hour
increase rate of FABP) − 0.4054 × (enzymatic
infarct size). The negative value of b2 corrects
for the extra rapid first hour increase rates in
case of larger infarctions.
COMPARISON OF FABP, MYOGLOBIN, AND CK-MB
AS REPERFUSION MARKERS
As with FABP, the reperfusion predicting
model was improved when the first hour
increase in myoglobin release was combined
with enzymatic infarct size (the values of b0,
b1, and b2 were 1.6839, 0.0034, and −0.3905,
respectively, while ROC curve areas for my-
oglobin alone and for myoglobin in combina-
tion with enzymatic infarct size were 0.718 and
0.857, p = 0.004, fig 3A and 3B). The area
under the ROC curve of the first hour increase
rate of CK-MB release was also augmented by
adding enzymatic infarct size to the model
(0.681 and 0.769, respectively, p = 0.04; values
of b0, b1, and b2 were 1.9102, 0.0736, and
−0.2402, respectively.). The areas under the
ROC curve for the first hour increase in FABP
and myoglobin release combined with enzy-
matic infarct size were both larger than for
CK-MB (p = 0.046 and p = 0.028, respec-
tively) (fig 3A and 3B).
Using the ROC curves, optimum points
(giving the maximum sum of sensitivity and
specificity) of the first hour increase in release
of FABP, myoglobin, and CK-MB were deter-
mined. In addition to sensitivity and specificity,
the positive and negative predictive values were
calculated at these points (table 2). Various
probabilities of reperfusion predicted by FABP
are also shown in combination with these vari-
ables (table 3).
Discussion
In this multicentre study, FABP was used as a
marker to distinguish successful reperfusion
from persistent occlusion after thrombolytic
treatment in a large group of patients with
confirmed acute myocardial infarction. The
definition of reperfusion was either TIMI 2+3
score or TIMI 3 score alone. Our findings
indicate that the best discrimination between
reperfusion and occlusion by plasma FABP or
myoglobin was obtained when TIMI 2+3 were
classified as reperfusion and TIMI 0+1 as
occlusion. FABP was found to perform as well
as plasma myoglobin, while both variables
performed better than CK-MB. For acute
clinical decision making, the accuracy of the
first hour increase in FABP release appeared
too low. However, in retrospective studies it
may be useful to include both the first hour
increase in FABP (or myoglobin) release and
the enzymatic infarct size in the predictive
model.
FIRST HOUR INCREASE RATE OF FABP RELEASE
AFTER THROMBOLYSIS AS A REPERFUSION MARKER
FABP is a small cytoplasmic protein (15 kDa),
like myoglobin (17.8 kDa), which is rapidly
released from injured myocardium and enters
the bloodstream when the occluded artery is
reopened by thrombolytic agents.21 22 Peak
values are reached on average within six hours
after the onset of acute myocardial infarction
and return to normal within 24 hours.8 21 22
Earlier studies used the time to the peak plasma
concentration to assess the value of serum
markers for discriminating between reperfused
and non-reperfused patients. For myoglobin,
Figure 3 Comparison of fatty acid binding protein
(FABP) with myoglobin (MYO) and creatine kinase MB
isoenzyme (CK-MB). (A) Receiver operating
characteristic (ROC) curves (sensitivity v 1 − specificity)
of the first hour increase in release of FABP (empty
squares), myoglobin (filled circles), or CK-MB (empty
triangles), for TIMI grades 2+3 v TIMI 0+1. (B) ROC
curves combining the first hour increase in release of FABP
(empty squares), myoglobin (filled circles), or CK-MB
(empty triangles) with QHBDH72, for TIMI 2+3 v TIMI
0+1.
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Table 2 Sensitivity, specificity, positive predictive value (PPV), and negative predictive
value (NPV) at optimal points in the receiver operating characteristic (ROC) curve
(maximum sum of sensitivity and specificity) for the various reperfusion markers
Probability of
reperfusion (q)
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
First hour increase rate of:
FABP (µg/l/h) 0.66 71 69 87 44
Myoglobin (µg/l/h) 0.67 67 71 88 42
CK-MB (U/l/h) 0.73 52 75 87 34
QHBDH72 plus first hour increase rate of:
FABP (µg/l/h) 0.78 74 93 97 55
Myoglobin (µg/l/h) 0.78 73 89 95 52
CK-MB (U/l/h) 0.75 77 71 89 50
CK-MB, creatine kinase MB isoenzyme; FABP, fatty acid binding protein; QHBDH72, cumulative
release of á hydroxybutyrate dehydrogenase in the first 72 hours.
Table 3 Sensitivity, specificity, positive predictive value (PPV), and negative predictive
value (NPV) for reperfusion, using the composite variable q (probability of reperfusion)
Probability of reperfusion (q) Sensitivity (%) Specificity (%) PPV (%) NPV (%)
0.20 98 14 77 67
0.40 97 31 81 75
0.55 90 52 85 63
0.60 87 66 88 63
0.77 76 90 96 55
0.80 73 93 97 54
0.95 30 97 97 32
Values for q were calculated from the first hour increase rate of plasma fatty acid binding protein
(FABP) and enzymatic infarct size according to the equation:
Log (q/1−q) = 1.6542 + 0.0132 × (first hour increase rate of FABP) − 0.4054 × (QHBDH72),
where QHBDH72 = cumulative release of á hydroxybutyrate dehydrogenase in the first 72 hours.
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Zabel and colleagues showed that measurement
of the early initial slope gives a more accurate
assessment of reperfusion than the time to peak
concentration, and it is also more rapidly avail-
able.6 The first hour increase in release can be
assessed either as an absolute value (value at
time t − value at time 0/dt) or relatively (value
at time t/value at time 0). In an ROC curve
analysis for myoglobin, Tanasijevic and col-
leagues found no diVerences in discrimination
when comparing absolute or relative early slope
values.23 In the present study the absolute first
hour increase in FABP release was assessed,
and the individual data showed great variation
and considerable overlap in the first hour
release values among the various TIMI scores.
DEFINITION OF REPERFUSION
In many studies, TIMI 2 and 3 patients have
been grouped and classified as being
reperfused.6 7 21 23–27 However, a study by An-
derson and colleagues showed that TIMI grade
3 blood flow resulted in improved patient out-
come compared with grade 2 flow.28 For this
reason, the TIMI 3 score alone may be defined
as successful reperfusion, while the TIMI 2
score represents an intermediate point between
TIMI 3 and TIMI 0+1. In the present study we
considered both TIMI 3 only and TIMI 2+3
combined as reperfusion. The results for TIMI
3 v TIMI 0+1 or v 0+1+2 were less
satisfactory, while the best performance with
FABP was obtained when both TIMI 2 and 3
groups were considered as being reperfused.
The results were similar for myoglobin and
CK-MB (data not shown). Hence FABP may
be useful as a reperfusion marker in discrimi-
nating between TIMI 2+3 v TIMI 0+1, but
not in diVerentiating between TIMI 2 or TIMI
3. Similarly, Christenson and colleagues re-
ported a better performance for myoglobin
when TIMI 2+3 were compared with TIMI
0+1, rather than when comparing TIMI 3 with
TIMI 0+1+2.27 Moreover, Apple recently con-
cluded that TIMI 3 flow patients cannot be
diVerentiated from TIMI 2 patients by using
biochemical markers.29
INCLUDING INFARCT SIZE IN THE MODEL
When the amount of necrosis is small, the first
hour increase in release of cell components
may be low and values found in the reperfused
group may overlap with those seen in patients
without reperfusion but with larger infarcts.
This overlap can be reduced when rates of
release are combined with enzymatic infarct
size in the model. However, a drawback of
using the cumulative release of á hydroxybu-
tyrate dehydrogenase over 72 hours as a meas-
ure of infarct size is the long time necessary for
sample collection; hence this method is only
useful in retrospective studies. Because of this,
we also evaluated the use of the sum of the ini-
tial ST elevations as a surrogate for infarct size.
A very weak correlation was found between the
sum of ST elevations and the cumulative
release of á hydroxybutyrate dehydrogenase
over 72 hours (r = 0.36, fig 4). Similarly,
Willems and colleagues also showed a poor
correlation between the sum of the initial ST
elevations and enzymatic infarct size
(r = 0.32).30 On the other hand, Yusuf and
associates found a much higher correlation
(r = 0.73), but they used a more refined
technique (precordial mapping) to evaluate ST
deviations.31 Using the sum of ST segment
elevation in our study, no improvement of dis-
crimination between reperfused and non-
reperfused patients could be obtained (fig 2B).
COMPARISON OF FABP, MYOGLOBIN, AND CK-MB
AS REPERFUSION MARKERS
Various biochemical markers of myocardial
necrosis have been used to detect reperfusion
non-invasively after thrombolysis. These in-
clude measurement of myoglobin and CK-
MB.5 6 25–27 In the present study, we compared
FABP with myoglobin and CK-MB as reper-
fusion marker by ROC curve analysis. Similar
results were found for FABP and myoglobin,
while CK-MB was slightly worse as a reper-
fusion marker. These findings are in line with
earlier studies in indicating more accurate
detection of reperfusion by myoglobin than by
CK-MB,6 24 25 while in a very recent study by
Ishii and colleagues on 45 patients, comparable
results were obtained for FABP and my-
oglobin.21 FABP is relatively more cardiospe-
cific than myoglobin as the (heart type) FABP
content of skeletal muscle is considerably less
than in cardiac muscle, while the muscular
content of myoglobin is approximately twice
that of the heart (when expressed per g wet
weight of muscle).22 In case of muscle injury—
for example, electrical defibrillation, intramus-
cular injection, or trauma—the serum concen-
tration of myoglobin will rise rapidly and hence
false positive results could be obtained. How-
ever, in the present work, as well as in that of
Ishii and colleagues, patients with these condi-
tions were excluded.21
The sensitivity and specificity of FABP,
myoglobin, and CK-MB, calculated at the opti-
mum points of the ROC curve, were not as high
in the present study as in others (table 4). This
may reflect the fact that in the present study
blood sampling was not accompanied by re-
peated angiography and so the exact timing of
the reopening of the vessel was not known.
Increased rates of cell component release were
determined during the first hour after thrombo-
lytic treatment, while the angiogram was taken
Figure 4 Scatterplots of infarct size estimated from the
sum of ST segment elevations in the admission ECG and
from cumulative release of á hydroxybutyrate
dehydrogenase during 72 hours (QHBDH72). The best fit
straight line (drawn) is shown.
5.0
4.0
2.0
3.0
1.0
0.0
20
QHBDH72 (g eq/l)
S
T
 a
t 
ad
m
is
si
o
n
 (
m
V
)
15
y = 0.09x + 0.68
R2 = 0.13
100 5
Assessment of reperfusion from plasma fatty acid binding protein 283
www.heartjnl.com
 on 17 October 2006 heart.bmjjournals.comDownloaded from 
later (between 0.9 and 2.0 hours after treat-
ment). A discrepancy between protein indices
and angiographic assessment of reperfusionmay
have occurred in patients with late reperfusion,
early spontaneous reperfusion, or reocclusion of
the infarct related artery after initial successful
thrombolysis. In an attempt to account for late
reperfusion, we added the increase rate of FABP
(per hour) at 1–3 hours after thrombolytic treat-
ment to our model, but no additional discrimi-
nation was obtained. However, the possibility of
early spontaneous reperfusion or reocclusion
after initial successful thrombolysis could not be
excluded, because a pretreatment coronary
angiogram was missing and because of insuY-
cient blood sampling. Notwithstanding these
considerations, our data still allow an adequate
comparison of the performance of the three
plasma markers studied.
CLINICAL APPLICATIONS
In the absence of angiography, it is important
that the FABP test can identify patients with
persistent occlusion, because such patients can
be treated by other interventions such as rescue
percutaneous transluminal coronary angio-
plasty. Thus both the negative predictive value
and the specificity were considered. At the opti-
mal point in the curve, the negative predictive
value—indicating the percentage of correctly
identified patients with decreased rates of
release—was low (table 2). The negative predic-
tive value is related to the prevalence of
non-reperfused patients, which was relatively
low (25%) in the present study. The optimum
specificity of the first hour increase in release of
FABP was 69%. In practice, this would mean
that on the basis of the first hour increase in
FABP release, 31% of the patients with TIMI 0
or 1 score would not be treated further after fail-
ing thrombolytic treatment—a rather high per-
centage. When the specificity increases—that is,
fewer patients with closed infarct related arteries
are missed—the sensitivity simultaneously de-
creases (more patients with adequate perfusion
after thrombolytic treatment will be treated
unnecessarily). It depends on the clinical
management which factor (sensitivity or specifi-
city) is regarded as the most important. By using
two probability values and disregarding the
patients who fell in between, a population of
patients with acute myocardial infarction treated
with thrombolytic agents and without coronary
angiography could be divided into a reperfused
group and a non-reperfused group. Table 3
shows that in this way a group of patients with a
> 97% chance of successful reperfusion and a
group with a > 75% chance of non-reperfusion
could be obtained by retrospective study. The
latter figure of 75% is relatively low because of
the low first hour increase in rate of FABP in
reperfused patients with small infarcts. This fig-
ure would thus have been higher if our analyses
had been restricted to patients with a certain
minimum infarct size (for example, 1 g eq/l).
The performance of FABP as a reperfusion
marker is greatly improved by including
enzymatic infarct size in the model. For exam-
ple, a patient with an average first hour increase
of plasma FABP of 200 µg/l/h and a large
infarct (> 10 g eq/l)—according to the formula
presented in the legend to table 3—would only
have a < 63% chance (that is, q = 0.63) of suc-
cessful reperfusion, whereas if this patient had
a small infarct (< 1 g eq/l) the chance of
successful reperfusion would be > 99% (that is,
q = 0.99).
CONCLUSIONS
As a non-invasive reperfusion marker, FABP
performs as well as myoglobin. Our data
indicate that for acute clinical decision making
there is inadequate discrimination between
reperfusion and non-reperfusion using this
method, but in retrospective studies discrimi-
nation can be improved by considering both
the increase rate of plasma FABP and the
enzymatically determined infarct size.
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IMAGES IN CARDIOLOGY
Pneumopyopericardium, complicating penetrating
gastric ulcer
A 66 year old man was admitted because of
monosymptomatic fever. Acute laboratory
findings indicated severe infection and ECG
showed low voltage and atrial fibrillation with a
heart rate of 116 beats/min. A chest radiograph
(right) showed pneumopericardium, making
transthoracic echocardiography (TTE) impos-
sible. Transoesophageal echocardiography
(TOE), however, disclosed normal heart func-
tion but echodense material indicating pus in
the pericardium behind the heart. Surgery and
endoscopy showed pneumopyopericardium
caused by a gastric ulcer, penetrating through
the diaphragm to the pericardium. The patient
was treated successfully with pericardial drain-
age, prolonged antibiotic therapy, and surgical
resection of the gastropericardial fistula.
Gastrointestinal fistula’s are well established
causes of pneumo- and pyopericardium.
Chest radiography is an excellent imaging
technique for establishing the diagnosis of
pneumopericardium but is of limited value in
the analysis of a potential cardiac component
of shock. In such cases, where air obstructs the
window of TTE, TOE may be useful.
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